

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Bosutinib for untreated chronic myeloid leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the scoping process a stakeholder commented that when tyrosine kinase inhibitor (TKI) therapy fails, the remaining treatment options may discriminate against people with non-European ethnic origins, who are less likely to have an available matched unrelated donor for stem cell transplant, and those with pre-existing co-morbidities which may preclude use of 2 <sup>nd</sup> generation TKI therapy.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The current options for people with CML will be taken into account during the committee's discussions about the role of bosutinib in the current treatment pathway.
---

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No additional stakeholders have been identified.

**Approved by Associate Director (name):** .....Frances Sutcliffe.....

**Date:** 12/03/2018